Disease relevance of SLC36A2

• Polymorphisms in human SLC36A2 exclude it as a candidate locus for a peripheral neuropathy that has been mapped to 5q31-33 [1].

High impact information on SLC36A2

• The chromosomal mutants PRO1 and PAT2 contain a single wild beet minichromosome with centromere activity and provide, together with cloned centromeric DNA sequences, an experimental system toward the molecular isolation of individual plant centromeres [2].
• RESULTS: Both PAT1 and PAT2 bind to and condense DNA into small particles as shown by laser scattering techniques [3].
• Gene delivery by PAT2/DNA complexes is chloroquine-dependent, can be blocked completely by free ligand (CSIPPEVKFNKPFVFLI), and is highly efficient (e.g. approximately five-fold more effective than lipofectamine) [3].
• Like glyceraldehyde-3-phosphate dehydrogenase, the beta-tubulin amino acid sequence was identical in all Phaeosphaeria species used in this study, with the exception of the two Pat2 isolates [4].
• Prespecified pattern 1 was identified in 81%, PAT 2 in 8%, and PAT 3 in 11% of the patients [5].

Biological context of SLC36A2

• Both PAT1 and PAT2 mediate 1:1 symport of protons and small neutral amino acids such as glycine, alanine, and proline [6].

Anatomical context of SLC36A2

• The human PAT1 and PAT2 transporters when functionally expressed in Xenopus laevis oocytes show characteristics similar to those of their mouse counterparts [7].

Other interactions of SLC36A2

• We recently cloned and functionally characterized two novel proton/amino acid transporters (PAT1 and PAT2) from mouse [7].

Analytical, diagnostic and therapeutic context of SLC36A2

• Perfusion: Time-resolved 3D GRE pulse sequence (FLASH, TE/TR/alpha: 0.8/1.9 ms/40 degrees ), parallel imaging (GRAPPA, PAT 2) [8].

References